Ornithine Canon, 3 g 10 pcs

Pharmacotherapeutic group

Phypoazotemic agent

ATX code: A05BA

Pharmacological properties

It has detoxifying action, reducing elevated ammonia levels in the body, in particular in liver diseases. The action of the drug is associated with its participation in the ornithine cycle of urea formation of Krebs (activates the cycle by restoring the activity of liver cells enzymes: ornithine carbamoyltransferase and carbamoylphosphate synthase). Promotes the production of insulin and somatotropic hormone. Improves protein metabolism in diseases requiring parenteral nutrition. Helps to reduce asthenic, dyspeptic and pain syndromes, as well as normalization of increased body weight (in steatosis and steatohepatitis).

Pharmacokinetics

L-ornithine-L-aspartate quickly dissociates into its components – ornithine and aspartate, and starts working within 15-25 minutes with a short half-life. It is excreted with the urine through the urea cycle.

Indications

Acute and chronic liver diseases accompanied by hyperammonemia.
Hepatic encephalopathy (latent and severe). Steatosis and steatohepatitis (of various origins).

Pharmacological effect

Pharmacotherapeutic group

Hypoazotemic agent

ATX code: A05BA

Pharmacological properties

It has a detoxifying effect, reducing elevated levels of ammonia in the body, in particular in liver diseases. The effect of the drug is associated with its participation in the ornithine Krebs urea cycle (activates the cycle, restoring the activity of liver cell enzymes: ornithine carbamoyltransferase and carbamoylphosphate synthase). Promotes the production of insulin and growth hormone. Improves protein metabolism in diseases requiring parenteral nutrition. Helps reduce asthenic, dyspeptic and pain syndromes, as well as normalize increased body weight (with steatosis and steatohepatitis).

Pharmacokinetics

L-ornithine-L-aspartate quickly dissociates into its constituent components – ornithine and aspartate, and begins to act within 15-25 minutes, having a short half-life. It is excreted in urine through the urea cycle.

Special instructions

When diagnosing hepatic encephalopathy due to the underlying disease, it is necessary to exercise extreme caution when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Impact on the ability to drive vehicles and machinery

The drug Ornithine Canon does not affect the ability to drive vehicles or engage in other potentially hazardous activities.

Active ingredient

Ornithine

Composition

Active substance:

L-ornithine-L-aspartate 3 g.

Excipients:

lemon flavor 0.015 g,

mint flavoring 0.005 g,

aspartame 0.05 g,

anhydrous citric acid 0.5 g,

mannitol 1.430 g.

Contraindications

Severe renal failure with a creatinine level of more than

3 mg/100 ml, hypersensitivity to the components of the drug, lactation period, children under 18 years of age (due to insufficient data).

With caution

Pregnancy.

Side Effects

The frequency of adverse reactions is presented according to the following classification (World Health Organization classification):

infrequently from > 1/1000 to < 1/100,

very rare from <1/10000, including isolated reports,

frequency unknown (frequency cannot be calculated from available data).

Immune system disorders

frequency unknown: allergic reactions.

Gastrointestinal disorders

uncommon: nausea, vomiting, abdominal pain, flatulence, diarrhea.

Musculoskeletal and connective tissue disorders

very rarely: pain in the limbs.

Interaction

Not described.

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

2 years.

Manufacturer

Kanonpharma production CJSC, Russia